BOSTON, Aug. 04, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today reported financial results for the quarter ended June 30, 2016.
"Our clinical development program for omadacycline continues to progress well. We have successfully completed our Phase 3 registration study in Acute Bacterial Skin and Skin Structure infections (ABSSSI), and our Phase 3 study in community acquired bacterial pneumonia (CABP) continues to progress according to plan. With our progress to date, we remain on track to file a new drug application for omadacycline in the United States in the first half of 2018,” said Michael Bigham, Chairman and Chief Executive Officer, Paratek. “In parallel, we are continuing to expand the potential clinical applications of omadacycline. Enrollment in our Phase 1b study with omadacycline for the treatment of urinary tract infections (UTI) is nearly complete, with top-line data expected in Q4; and we expect to initiate enrollment this month in our Phase 3 study with omadacycline for the oral-only treatment of ABSSSI.”
"Our clinical development program for omadacycline continues to progress well. We have successfully completed our Phase 3 registration study in Acute Bacterial Skin and Skin Structure infections (ABSSSI), and our Phase 3 study in community acquired bacterial pneumonia (CABP) continues to progress according to plan. With our progress to date, we remain on track to file a new drug application for omadacycline in the United States in the first half of 2018,” said Michael Bigham, Chairman and Chief Executive Officer, Paratek. “In parallel, we are continuing to expand the potential clinical applications of omadacycline. Enrollment in our Phase 1b study with omadacycline for the treatment of urinary tract infections (UTI) is nearly complete, with top-line data expected in Q4; and we expect to initiate enrollment this month in our Phase 3 study with omadacycline for the oral-only treatment of ABSSSI.”
